Recent U.S. case law is reshaping the risks around skinny labelling strategies for generics. What was once seen as a safe regulatory pathway now raises new concerns about infringement. With a pending petition before the U.S. Supreme Court, the industry awaits clarity on the boundaries of induced infringement.

Read Anna-Kathrine Fevre‘s take on what both originators and generics should watch out for here.